Novo Nordisk A/S
NVOToday
-3.07%
5 Days
-4.50%
1 Month
-6.58%
6 Months
-6.39%
Year to Date
-36.79%
1 Year
-54.01%
TradingKey Stock Score of Novo Nordisk A/S
Currency: USD Updated: 2025-10-17Key Insights
The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Novo Nordisk A/S's Score
Support & Resistance
Score Analysis
Analyst Rating
Novo Nordisk A/S Highlights
Novo Nordisk A/S is a Danish multinational pharmaceutical firm headquartered in Bagsværd, with manufacturing facilities across nine countries and affiliates or offices in five others. The company is predominantly controlled by its majority shareholder, Novo Holdings A/S, which owns approximately 28.1% of its shares and a majority of its voting rights.
Novo Nordisk specializes in the production and marketing of pharmaceutical products and services, focusing primarily on diabetes care medications and devices. Among its key products is semaglutide, utilized for diabetes treatment under the brand names Ozempic and Rybelsus, as well as for obesity treatment under the brand name Wegovy. The company also engages in hemostasis management, growth hormone therapy, and hormone replacement therapy, producing numerous drugs under various brand names such as Levemir, Tresiba, NovoLog, Novolin R, NovoSeven, NovoEight, and Victoza.
Employing over 48,000 individuals worldwide, Novo Nordisk distributes its products in 168 countries. The corporation was formed in 1989 from a merger of two Danish companies with origins tracing back to the 1920s. The Novo Nordisk logo features the Apis bull, a sacred animal from ancient Egypt, represented by the hieroglyph 𓃒. Novo Nordisk is also a full member of the European Federation of Pharmaceutical Industries and Associations.
Recognized for its workplace culture, the company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, later ranking 72nd in 2014 and 73rd in 2017. In January 2012, Novo Nordisk was acclaimed as the most sustainable company globally by Corporate Knights, while its spin-off, Novozymes, secured the fourth position. The company is a leader in the FTSE4Good Index and stands as the only European firm in the top ten list. As the largest pharmaceutical company in Denmark, Novo Nordisk's market capitalization surpassed the GDP of Denmark's domestic economy in 2023, making it the highest valued company in Europe, with net sales reaching US$42.121 billion in 2024.
News
Lilly, Novo Nordisk Shares Plummet as Trump Announces Price Cut to Ozempic
TradingKey - On Thursday, October 16, shares of Eli Lilly and Novo Nordisk fell sharply in after-hours trading after President Donald Trump announced a significant price reduction for the diabetes drug Ozempic. As of the time of writing, Eli Lilly (LLY) was down more than 5%, and Novo Nordisk (NVO)
Eli Lilly, Novo Nordisk shares fall after Trump targets weight-loss drugs
Shares of weight-loss drug developers Eli Lilly LLY.N and U.S.-listed shares of Novo Nordisk NOVOb.CO fall premarket
Novo Nordisk's New CEO Makes $5.2B Bet on Liver Disease Treatment Through Akero Acquisition
TradingKey - Danish pharmaceutical giant Novo Nordisk announced on Thursday that it will acquire U.S. biotechnology company Akero Therapeutics for a total consideration of up to $5.2 billion.
Quantum Meets Medicine: Novo Nordisk and Denmark Back Global Flagship Quantum Venture Fund
TradingKey - As Novo Nordisk faces growing pressure in the U.S. weight-loss drug market, the Danish pharmaceutical giant is accelerating its push into a futuristic frontier: quantum computing for medicine. In a major move, it has partnered with the Danish government to invest in the world’s largest
[Reuters Breakingviews] Obesity kings’ buffet is slimmer than it looks
Obesity kings’ plump future is under siege. Over the past month Roche ROG.S and Pfizer PFE.N have splurged over $10 billion scooping up promising treatments and other rivals are rapidly developing their own medicines. Incumbents $242 billion Novo Nordisk NOVOb.CO and $722 billion Eli Lilly LLY.N may
Why BioNTech Stock Jumped by Nearly 4% on Wednesday
Key PointsThe biotech continues to embrace artificial intelligence (AI) technology, which is heartening for investors.It owns and manages an AI developer, InstaDeep.10 stocks we like better than BioNTech Se › Germany-based BioNTech (NASDAQ: BNTX) saw its U.S. listed stock enjoy a mini-pop on Wednesd
Financial Indicators
EPS
Total revenue
Novo Nordisk A/S Info
Novo Nordisk A/S is a Danish multinational pharmaceutical firm headquartered in Bagsværd, with manufacturing facilities across nine countries and affiliates or offices in five others. The company is predominantly controlled by its majority shareholder, Novo Holdings A/S, which owns approximately 28.1% of its shares and a majority of its voting rights.
Novo Nordisk specializes in the production and marketing of pharmaceutical products and services, focusing primarily on diabetes care medications and devices. Among its key products is semaglutide, utilized for diabetes treatment under the brand names Ozempic and Rybelsus, as well as for obesity treatment under the brand name Wegovy. The company also engages in hemostasis management, growth hormone therapy, and hormone replacement therapy, producing numerous drugs under various brand names such as Levemir, Tresiba, NovoLog, Novolin R, NovoSeven, NovoEight, and Victoza.
Employing over 48,000 individuals worldwide, Novo Nordisk distributes its products in 168 countries. The corporation was formed in 1989 from a merger of two Danish companies with origins tracing back to the 1920s. The Novo Nordisk logo features the Apis bull, a sacred animal from ancient Egypt, represented by the hieroglyph 𓃒. Novo Nordisk is also a full member of the European Federation of Pharmaceutical Industries and Associations.
Recognized for its workplace culture, the company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, later ranking 72nd in 2014 and 73rd in 2017. In January 2012, Novo Nordisk was acclaimed as the most sustainable company globally by Corporate Knights, while its spin-off, Novozymes, secured the fourth position. The company is a leader in the FTSE4Good Index and stands as the only European firm in the top ten list. As the largest pharmaceutical company in Denmark, Novo Nordisk's market capitalization surpassed the GDP of Denmark's domestic economy in 2023, making it the highest valued company in Europe, with net sales reaching US$42.121 billion in 2024.
Related Instruments
Popular Symbols
